23 May, 2026
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on…
WASHINGTON — A group of Senate Democrats is proposing that Medicare cover in-home care, which would create the first new benefit in the program since the Part D retail drug…
The Trump administration has made sweeping changes to vaccine policy over the past year justified by invocations of patients’ “personal autonomy.” In January, Department of Health and Human Services head…
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Shelley Wood and Eric Topol. Be sure to sign up for the weekly “First Opinion Podcast”…
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on…

Medicare is in desperate need of DOGE deregulation

Lost amid the turmoil of DOGE’s federal workforce cuts was a mid-February executive order directing DOGE to repeal regulations that impede innovation, are overly burdensome, or not clearly authorized by statute. Now it appears that DOGE and the Trump administration are taking action on that order. The administration has even created a website, regulations.gov, where […]

4 mins read

Women’s Health Initiative to receive NIH funding after all

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. On Monday, the groundbreaking Women’s Health Initiative announced that the federal contracts funding the study’s 40 regional centers would end with the fiscal year. But on Thursday a federal official said the Department of Health and Human Services was reversing […]

1 min read

Bristol’s Cobenfy disappoints as supplemental antipsychotic drug

A landmark new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday. The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades. Doctors […]

1 min read